Latest Breaking News On - Egardless of their gender quot about biosense webster is the global market leader in science and technology behind diagnosis treatment cardiac arrhythmias part johnson amp medtech - Page 1 : comparemela.com
A new report, including insights from international experts, reveals that Atrial Fibrillation diagnosis is more challenging in women, needing a tailored management approach SINGAPORE, Nov. 17, 2022 /PRNewswire/ Biosense Webster, Inc., part of Johnson & Johnson MedTech[], today announced the release of a report titled, 'Atrial Fibrillation Exacts Toll on Women: Addressing the Gender Disparity in the Treatment and Management of Atrial Fibrillation in the Asia-Pacific Region'. Endorsed by the Asia Pacific Heart Rhythm Society (APHRS), the report brings together a panel of experts from various geographic locations including Australia, China, Japan, and Singapore, among others to address the unique features of Atrial Fibrillation (AFib) in women and provide recommendations for improving its management across the region. AFib is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide.[1] It is a progressive disease, and if left untreated, can g